Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07032714 · ClinicalTrials.gov registry record · Phase 1
Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT07032714: Recruiting Phase 1 study, sponsored by Massachusetts General Hospital.
NCT07032714 is a Phase 1 study that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07032714, a Phase 1 study, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a phase 1 study to find the recommended dose and schedule of mezigdomide and talquetamab in relapsed and refractory multiple myeloma (RRMM), and to test the effects of the drugs on cancer. Cohort A will receive talquetamab + dexamethasone, then mezigdomide + talquetamab,+ dexamethasone. After Cohort A, Cohort B will evaluate mezigdomide + dexamethasone followed by step-up dosing of talquetamab (mezigdomide + talquetamab,+ dexamethasone).
Interventions
- DRUG Dexamethasone
- DRUG Talquetamab
- DRUG Mezigdomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-12-19 |
| Est. Completion | 2028-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07032714
The ClinicalTrials.gov registry entry for NCT07032714 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT07032714 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07032714 about?
NCT07032714 is a clinical study titled "Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma". This is a phase 1 study to find the recommended dose and schedule of mezigdomide and talquetamab in relapsed and refractory multiple myeloma (RRMM), and to test the effects of the drugs on cancer. Cohort A will receive talquetamab + dexamethasone, then mezigdomide + talquetamab,+ dexamethasone. Afte...
What is the current status of trial NCT07032714?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2025-12-19. Estimated completion is 2028-07-01.
What interventions are being tested in trial NCT07032714?
The interventions under investigation include: Dexamethasone (DRUG), Talquetamab (DRUG), Mezigdomide (DRUG).
Who is sponsoring clinical trial NCT07032714?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.